NAD+ Research Compound Guide 2026 — Molecular Profile, Sirtuin & PARP Mechanism, and Verification

NAD+ — nicotinamide adenine dinucleotide — is one of the most heavily studied small molecules in modern cell biology, and unlike most compounds in the research-peptide market it is not a peptide at all. It is a dinucleotide coenzyme present in every living cell, functioning simultaneously as the central electron carrier of metabolism and as the consumable substrate for three families of NAD+-dependent enzymes: the sirtuins, the poly(ADP-ribose) polymerases (PARPs), and the CD38/CD157 NADases. Because those enzyme families sit at the intersection of energy metabolism, DNA-damage signaling, and cellular aging research, NAD+ and its biosynthetic precursors have become reference reagents in laboratories studying mitochondrial bioenergetics, redox biology, and the enzymology of aging.

This guide is written for qualified laboratory researchers sourcing NAD+ as a research compound. It covers the molecular profile, the mechanism at the coenzyme and enzyme-pathway level as described in the published literature, representative preclinical research data, real citations you can verify yourself through PubMed and PubMed Central, the in-vitro use cases in which NAD+ appears, and how to evaluate the analytical documentation that should accompany a hygroscopic dinucleotide of this kind. It also situates NAD+ within the current U.S. regulatory context, which differs from that of the peptides on the July 2026 compounding-review docket.

For in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use.

Section 1 — Molecular Profile

NAD+ is a dinucleotide: two nucleotides — one bearing a nicotinamide base, the other an adenine base — joined tail-to-tail through a pyrophosphate bridge. The oxidized form carries a net positive charge on the nicotinamide ring nitrogen, which is the convention the “+” in NAD+ denotes.

• Compound name: β-Nicotinamide adenine dinucleotide (oxidized form); commonly written NAD+
• CAS number: 53-84-9 (free acid); disodium and hydrate forms carry separate CAS numbers
• Molecular formula: C₂₁H₂₇N₇O₁₄P₂ (free acid)
• Molecular weight: ≈ 663.43 g/mol (free acid)
• Class: Pyridine dinucleotide coenzyme (not a peptide)
• Components: Nicotinamide mononucleotide (NMN) moiety + adenosine monophosphate (AMP) moiety, linked by a pyrophosphate
• Redox partner: NADH (the two-electron-reduced form)
• Appearance: White to off-white hygroscopic lyophilized powder; readily soluble in aqueous buffer

Two properties matter for sourcing. First, NAD+ is strongly hygroscopic and is not indefinitely stable in solution — it hydrolyzes and can degrade to nicotinamide and ADP-ribose, so genuine material is supplied lyophilized and a competent COA should report purity on the dry solid. Second, NAD+ exists in a redox pair with NADH and is closely related to the phosphorylated coenzymes NADP+/NADPH; these relatives share much of the molecule and can appear as impurities. That makes chromatographic purity and mass-spectrometric identity — a protonated-molecule signal consistent with a ~663 Da dinucleotide — more meaningful than a purity figure alone, because a purity number cannot by itself distinguish NAD+ from its reduced or phosphorylated cousins.

At roughly 663 g/mol, NAD+ is a compact, well-characterized molecule whose UV absorbance (a strong adenine-driven band near 260 nm, and the distinct NADH band near 340 nm that NAD+ lacks) gives analysts an additional, orthogonal identity handle alongside HPLC retention time and mass.

Section 2 — Mechanism (Pathway Language)

NAD+ is studied at two mechanistic levels: as a redox coenzyme and as an enzyme substrate. The published mechanistic literature describes it in terms of electron transfer, enzyme catalysis, and biosynthetic flux — not in terms of any clinical endpoint.

Redox coenzyme. In its best-known role, NAD+ is the mobile electron acceptor of catabolic metabolism. It is reduced to NADH in glycolysis, the tricarboxylic acid cycle, and fatty-acid oxidation, then re-oxidized at the mitochondrial electron-transport chain, coupling substrate oxidation to ATP synthesis. The NAD+/NADH ratio is a core readout of a cell’s metabolic and redox state in bioenergetic studies.

Sirtuin substrate. Beyond redox chemistry, NAD+ is consumed as a co-substrate by the sirtuins (SIRT1–SIRT7), a family of NAD+-dependent deacylases. Sirtuins cleave NAD+ to remove acetyl and other acyl groups from target proteins — histones, transcription factors, and metabolic enzymes — linking the cell’s NAD+ status to gene-expression and mitochondrial programs studied in aging and metabolism models.

PARP and CD38 consumption. Two further enzyme classes consume NAD+. The PARPs use NAD+ to build poly(ADP-ribose) chains during DNA-damage signaling and repair, and the ectoenzyme CD38 hydrolyzes NAD+ to generate cyclic ADP-ribose, a second messenger in calcium signaling. Because these NADases and the sirtuins draw on the same NAD+ pool, researchers study them as a competing, integrated network.

Biosynthesis and the salvage pathway. Cells maintain NAD+ through three routes: the de novo pathway from tryptophan, the Preiss–Handler pathway from nicotinic acid, and the salvage pathway that recycles nicotinamide. The salvage pathway is the dominant source in most tissues, and its rate-limiting enzyme, nicotinamide phosphoribosyltransferase (NAMPT), is a central focus of NAD+ metabolism research. The precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) feed this pathway and are the compounds most often compared with NAD+ itself in precursor studies.

In accordance with research-context framing, this article describes NAD+ strictly at the coenzyme and enzyme-pathway level. It is studied for its role in redox metabolism, sirtuin/PARP/CD38 enzymology, and NAD+ biosynthetic flux in controlled systems; no human outcome, therapeutic, or physiological benefit is claimed or implied.

Section 3 — Preclinical Research Data

The NAD+ literature is unusually deep, spanning enzymology, mitochondrial biology, and models of aging and metabolic stress. Several consistent experimental threads recur.

Age-associated NAD+ decline in model systems. A widely reported observation in preclinical work is that tissue NAD+ concentrations decline with age in rodent and invertebrate models, alongside shifts in the activity of NAD+-consuming enzymes. This finding motivates much of the mechanistic interest in NAD+ biosynthesis and is characterized in cell and animal systems rather than as a human clinical claim.

Precursor-supplementation studies. In preclinical rodent models, raising NAD+ availability with precursors such as NMN or NR has been reported to affect mitochondrial oxidative metabolism, SIRT1 and SIRT3 activity, and mitochondrial protein-acetylation status. A dedicated toxicology-style study reported that NMN administered to rats at 500 mg/kg/day for 91 days produced no adverse events, while the highest dose tested (2000 mg/kg/day) was associated with reduced body weight and food consumption — a preclinical safety-margin observation, not a human recommendation.

Enzyme-pathway characterization. Mechanistic studies continue to map how NAMPT, CD38, PARPs, and the sirtuins partition the shared NAD+ pool, including how NAMPT inhibition depletes cellular NAD+ and how CD38 activity contributes to NAD+ turnover. These are enzymology endpoints — cofactor concentrations, enzyme kinetics, acetylation state — measured in defined cell-based systems.

Across these studies the recurring experimental readout is a measurable molecular endpoint: the NAD+/NADH ratio, sirtuin or PARP activity, mitochondrial acetylation, or precursor flux, quantified in a defined cellular or animal model.

Section 4 — Published Literature (Verifiable Citations)

The following are real, published references retrievable through PubMed and PubMed Central (PMC). Researchers are encouraged to read the primary sources directly.

• Imai S, Guarente L. “NAD+ and sirtuins in aging and disease.” Trends in Cell Biology. 2014;24(8):464–471. PubMed: 24786309 — foundational review linking NAD+ availability to sirtuin activity in aging models.
• Verdin E. “NAD+ in aging, metabolism, and neurodegeneration.” Science. 2015;350(6265):1208–1213. PubMed: 26785480 — authoritative overview of NAD+ metabolism and its consuming enzymes.
• Rajman L, Chwalek K, Sinclair DA. “Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.” Cell Metabolism. 2018;27(3):529–547. PubMed: 29514064 — synthesis of the preclinical in-vivo evidence on NAD+ precursors.
• “Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.” 2023. PMC: PMC10692436 — review of NAD+-precursor supplementation and open questions.
• “Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases.” 2024. PMC: PMC10838897 — mechanistic review of NAD+ metabolism in neurodegeneration models.
• “A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models.” 2025. PMC: PMC11877801 — systematic review of NAD+-precursor effects in rodent cognitive models.
• Yang Y, et al. “An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR).” Food Frontiers. 2025 — comparative mechanistic review of the two principal NAD+ precursors.

Citing real primary literature is a core part of the PYXAX research-context standard. Any source — vendor or publication — that references “studies” without traceable identifiers should be treated with caution. Because NAD+ has both a vast basic-science literature and a separate consumer-supplement marketing history, the strongest evidentiary practice is to read the primary enzymology and preclinical reports directly and to keep clear the distinction between mechanistic research findings and marketing narratives.

Section 5 — Research Applications (In-Vitro Use Cases)

Within qualified laboratory settings, NAD+ is used as a reagent and reference compound across several categories of in-vitro and preclinical work:

• Enzyme cofactor supply — as the redox cofactor in dehydrogenase and oxidoreductase assays, where NAD+/NADH interconversion is the measured signal.
• Sirtuin enzymology — as the co-substrate in in-vitro sirtuin deacylation assays probing SIRT1–SIRT7 activity.
• PARP and DNA-damage research — as the ADP-ribose donor in PARP activity and poly(ADP-ribosyl)ation assays.
• NAD+ metabolism and flux studies — as a reference standard for quantifying cellular NAD+ pools and characterizing NAMPT, CD38, and salvage-pathway activity.
• Mitochondrial bioenergetics — as a component of respiration and redox-state measurements in isolated mitochondria and cell models.
• Analytical method development — as a defined dinucleotide standard for validating reversed-phase or ion-pair HPLC and LC-MS identity methods, including resolution from NADH, NADP+, and degradation products.

Each of these applications is an in-vitro or preclinical research use. Compounds supplied for research are not intended for, and must not be used in, any human or veterinary context.

Section 6 — How to Evaluate a Source

NAD+ is hygroscopic, redox-labile, and surrounded by closely related coenzymes, which makes analytical documentation more — not less — important. The following steps separate verifiable sourcing from marketing claims.

Step 1 — Confirm the exact molecule and form. The COA and product page should state that the material is the oxidized β-NAD+ free acid (or specify a named salt/hydrate), give the molecular formula C₂₁H₂₇N₇O₁₄P₂, and report a molecular weight near 663 g/mol. Ambiguity between NAD+, NADH, and NADP+ is a documentation gap, not a detail.

Step 2 — Confirm the testing laboratory is named. “Third-party tested” is meaningless without a named, accredited laboratory. Look for an ISO 17025-accredited facility or equivalent recognized accreditation, and a COA that names the lab that tested the specific batch.

Step 3 — Confirm identity by mass spectrometry. A genuine NAD+ sample should present a protonated- or deprotonated-molecule signal consistent with a ~663 g/mol dinucleotide on LC-MS. A COA that reports only “purity” without an identity mass is incomplete, because purity alone cannot distinguish NAD+ from its reduced or phosphorylated relatives.

Step 4 — Confirm chromatographic purity and check for related species. HPLC should show a single dominant peak. The relevant impurities to resolve are NADH, NADP+/NADPH, and hydrolysis products such as nicotinamide and ADP-ribose; a well-resolved method plus UV spectra (the absence of the 340 nm NADH band is itself informative) will reveal them.

Step 5 — Verify lot specificity and a complete panel. The batch number on the COA must match the vial label and correspond to the production lot — not a single historical testing event applied across an entire catalog. A COA you can verify independently, through a QR-linked laboratory portal or a searchable community database, is the standard to hold. For sensitive cell-based work, purity and identity should be accompanied by endotoxin and heavy-metal data, both of which can confound enzyme and cell assays.

Section 7 — Regulatory Context (July 2026)

Researchers sourcing NAD+ in the United States should understand how it sits in the current landscape. NAD+ is an endogenous coenzyme and is not a peptide, and it is not among the substances on the FDA compounding-review docket. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to consider a set of peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), epitalon, and semax — for potential inclusion on the Section 503A Bulk Drug Substances List; ahead of that meeting the FDA posted briefing materials proposing that the committee not add the substances, citing incomplete characterization and limited human safety and effectiveness data. PCAC recommendations are advisory only and are not final until the FDA issues its own determination. NAD+ and its precursors sit in a separate category and are subject to their own overlapping frameworks depending on how they are marketed; none of this changes the status of NAD+ supplied strictly for laboratory research. Researchers remain responsible for compliance with all applicable regulations in their jurisdiction. (See the PYXAX peptide-compliance landscape guide for the full regulatory picture.)

Section 8 — PYXAX Verification Standard

Every PYXAX batch is independently third-party tested by accredited laboratories including ILS Labs, Krause Analytical, and Janoshik. Batch-specific COAs are published for every lot, naming the accredited lab that tested that batch.

Testing panel:

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin (USP <85> LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number. The batch number on the vial matches the batch number on the COA in the PYXAX COA Library, so researchers can confirm identity — including the exact form and molecular weight supplied — before ordering.

Community verification. Select lots are submitted to Janoshik Analytical for community verification, with results publicly searchable by batch number — no vendor contact required. Founding batches were verified through Krause Analytical (accredited US laboratory), and ongoing production lots are tested across the accredited-laboratory network described above, with a batch-specific COA published for every lot.

View PYXAX NAD+ (Nicotinamide Adenine Dinucleotide) →
View COA Library →
Read The PYXAX Standard →

Additional resources: pyxax.com/shop/ · pyxax.com/coa-library/ · pyxax.com/standard/

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.